基于病例報(bào)告文獻(xiàn)的妊娠期使用磺達(dá)肝癸鈉安全性分析
中圖分類號(hào)R969.3;R973 文獻(xiàn)標(biāo)志碼A 文章編號(hào) 00-0408(2025)09-099-06
DOI0.6039/j.issn.00-0408.2025.09.4
ABSTRACTOBJECTIVEToevaluate thesafetyoffondaparinux inpregnancyandprovidereferenceforitsrational clinical application.METHODSAsearch wasconducted indatabases including CNKI,Wanfang,PubMed,Embase,andElsevier(the searchtimewasfromtheconstructionofthedatabasetoDecember17,2024)tocollctcasereportliteratureonfondapariuxuse duringpregnancy.Patientdemographicinformation,fondaparinuxuseduringpregnancy,concomitantmedications,clinical manifestations,andtreatment detailswereextractedfordescriptivestatisticalanalysis.RESULTSAtotalof17casereports regardingtheuseoffondaparinux during pregnancywerecolected,involving42patientsfrom1lcountriesand47pregnancy records.Amongthese,2Ocasesinvolvedtheuseoffondaparinuxforthepreventionofpregnancy-relatedvenous thromboembolism (VTE),while27cases werefondaparinux treatmentduetorelatedconditions.Atotalof29occurencesoftepatientsweretreated with fondapariuxduetoa(family)historyofVTE.Nineoccurencesofcomplicated pregnancieswerereported,and35patients hadecordsofcomorbiditiesorrelevant medical histories.Theadverseeventsthatocurredduringpregnancywiththeuseof fondaparinux includepostpartum hemorrhage(7cases)andexcesiveanticoagulationcausedbyinappropriate dosage(1case).
Among the 7 casesof postpartum hemorrhage,3 caseshada blood loss of no less than 1 0 0 0 m L (including 2 cases with uterine atony),3 cases had a drug discontinuation time of ? 1 2 h CONCLUSIONS Based on the existing literature,the safetyoffondaparinuxduringpregnancyisgenerally manageable,with the main adverse event being postpartum hemorrhage.The dosage,interval between discontinuation, comorbidities/medical history,andconcomitantmedicationsof fondaparinux may be the main causesof its adverse events.
KEYWORDSfondaparinux; pregnancy; safety evaluation;anticoagulation;casereport;literatureanalysis
妊娠期女性與非妊娠期女性相比,發(fā)生靜脈血栓栓塞(venousthromboembolism,VTE)的風(fēng)險(xiǎn)約增加了5倍;而在產(chǎn)褥期,該風(fēng)險(xiǎn)進(jìn)一步增加至20倍以上,且一直持續(xù)到產(chǎn)后12周。(剩余12143字)
- 《骨質(zhì)疏松癥臨床治療生物制劑循...
- 中美日藥品說明書適老化管理的對(duì)...
- 我國(guó)航空醫(yī)療救援藥品使用現(xiàn)狀分...
- 基于定性、定量及化學(xué)模式識(shí)別分...
- 溫脾通絡(luò)開竅方抑制AD小鼠神經(jīng)...
- 鉤苞大丁草的HPLC指紋圖譜建...
- 雙術(shù)湯對(duì)大鼠的安全性及改善消化...
- 指紋圖譜結(jié)合含量測(cè)定分析黃芪悶...
- 不同基原積實(shí)的多組分含量測(cè)定及...
- 匹妥布替尼在大鼠體內(nèi)的代謝產(chǎn)物...
- 檸檬苦素對(duì)妊娠期糖尿病大鼠腎臟...
- 司美格魯肽對(duì)比卡格列凈治療二甲...
- 兒童患者萬古霉素穩(wěn)態(tài)血藥濃度谷...
- 基于病例報(bào)告文獻(xiàn)的妊娠期使用磺...
- 難治性化療所致惡心嘔吐的列線圖...
- 不同劑型短效rhGH治療矮小癥...
- 我國(guó)醫(yī)療機(jī)構(gòu)藥學(xué)監(jiān)護(hù)開展現(xiàn)狀調(diào)...
- 利用ECHO模型評(píng)價(jià)藥學(xué)質(zhì)控對(duì)...
- 家庭醫(yī)生制度下藥師參與腦卒中患...
- 羅特西普治療骨髓增生異常綜合征...
- 替爾泊肽用于2型糖尿病和長(zhǎng)期體...
- 姜黃素抗抑郁作用機(jī)制的研究進(jìn)展...